modelFlucloxacillin
Extends from Pharmacolibrary.Drugs.ATC.J.J01CF05.
Information
| name: | Flucloxacillin | |
| ATC code: | J01CF05 | route: | oral |
| compartments: | 1 | |
| dosage: | 500 | mg |
| volume of distribution: | 10 | L |
| clearance: | 6.2 | L/h |
| other parameters in model implementation | ||
Flucloxacillin is a beta-lactam antibiotic of the penicillin class, primarily used to treat infections caused by susceptible Gram-positive bacteria, including staphylococcal infections. It is widely used and approved for medical use today for conditions such as skin, bone, and joint infections, as well as pneumonia and endocarditis.
Pharmacokinetics
Pharmacokinetic parameters in healthy adult volunteers following oral administration of flucloxacillin capsules.
References
Drennan, PG, et al., & Chambers, ST (2021). Population pharmacokinetics of free flucloxacillin in patients treated with oral flucloxacillin plus probenecid. British journal of clinical pharmacology 87(12) 4681–4690. DOI:10.1111/bcp.14887 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33963595
Öbrink-Hansen, K, et al., & Stilling, M (2022). Population Pharmacokinetics of Flucloxacillin In Bone and Soft Tissue- Standard Dosing is Not Sufficient to Achieve Therapeutic Concentrations. Pharmaceutical research 39(7) 1633–1643. DOI:10.1007/s11095-022-03197-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/35233728
Barker, CIS, et al., & Standing, JF (2023). The Neonatal and Paediatric Pharmacokinetics of Antimicrobials study (NAPPA): investigating amoxicillin, benzylpenicillin, flucloxacillin and piperacillin pharmacokinetics from birth to adolescence. The Journal of antimicrobial chemotherapy 78(9) 2148–2161. DOI:10.1093/jac/dkad196 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37531085
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)